S-equol was well tolerated and inhibited proliferation of breast tumor cells, as measured by a decrease in Ki-67 (8% compared to baseline)Up to 20% decrease in Ki- 67 was observed in 28% of S-equol-treated patients. Here, MKI67 is linked to breast neoplasm.